Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

G. Schifitto; D. R. Peterson; J. Zhong; H. Ni; K. Cruttenden; M. Gaugh; H. E. Gendelman; M. Boska; H. Gelbard

doi:10.1212/01.wnl.0000204294.28189.03

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

G. Schifitto, D. R. Peterson, J. Zhong, H. Ni, K. Cruttenden, M. Gaugh, H. E. Gendelman, M. Boska, H. Gelbard

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

Original language	English (US)
Pages (from-to)	919-921
Number of pages	3
Journal	Neurology
Volume	66
Issue number	6
DOIs	https://doi.org/10.1212/01.wnl.0000204294.28189.03
State	Published - Mar 2006

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/01.wnl.0000204294.28189.03

Cite this

@article{7128eecc5b444934be4e9440af3b36aa,

title = "Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report",

abstract = "In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.",

author = "G. Schifitto and Peterson, {D. R.} and J. Zhong and H. Ni and K. Cruttenden and M. Gaugh and Gendelman, {H. E.} and M. Boska and H. Gelbard",

note = "Funding Information: Supported by NIH grants P01 MH64570, U01 AI27658, and R01 MH64409 and General Clinical Research Center grant M01 RR00044 from the National Center for Research Resources, NIH. ",

year = "2006",

month = mar,

doi = "10.1212/01.wnl.0000204294.28189.03",

language = "English (US)",

volume = "66",

pages = "919--921",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Valproic acid adjunctive therapy for HIV-associated cognitive impairment

T2 - A first report

AU - Schifitto, G.

AU - Peterson, D. R.

AU - Zhong, J.

AU - Ni, H.

AU - Cruttenden, K.

AU - Gaugh, M.

AU - Gendelman, H. E.

AU - Boska, M.

AU - Gelbard, H.

N1 - Funding Information: Supported by NIH grants P01 MH64570, U01 AI27658, and R01 MH64409 and General Clinical Research Center grant M01 RR00044 from the National Center for Research Resources, NIH.

PY - 2006/3

Y1 - 2006/3

N2 - In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

AB - In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

UR - http://www.scopus.com/inward/record.url?scp=33645837210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645837210&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000204294.28189.03

DO - 10.1212/01.wnl.0000204294.28189.03

M3 - Article

C2 - 16510768

AN - SCOPUS:33645837210

SN - 0028-3878

VL - 66

SP - 919

EP - 921

JO - Neurology

JF - Neurology

IS - 6

ER -

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this